Vassilios Aslanis
First Name / Last Name : Vassilios Aslanis
Title or function : PharmD
Company : Galecto, Danmark
First Name / Last Name : Vassilios Aslanis
Title or function : PharmD
Company : Galecto, Danmark
Vassilios Aslanis holds a PharmD from Toulouse University and is specialized in pharmacokinetics with an initial training in pharmacometrics from Paris University.
Vassilios has been employed in the pharmaceutical industry as a clinical pharmacologist for over 17 years in different therapeutic areas (neuroscience, autoimmunity, and transplantation, and mainly in oncology).
He started his career in drug development at Pierre Fabre Pharmaceuticals in France (2003-2009).
Vassilios then joined Novartis in Basel, Switzerland (2009-2018), where he held positions of increasing responsibility in clinical pharmacokinetics and clinical pharmacology, also contributing to process improvement initiatives across the R&D organization.
Vassilios joined Ipsen (Paris, France) in 2018 as Head of Clinical Pharmacology for Oncology and Radioligand Therapy.
In 2021, he joined Galecto, a Swedish biotechnology company based in Copenhagen, Denmark, as Head of Clinical Pharmacology working on galectin-3 inhibitors in fibrosis and cancer.
Vassilios is actively involved in the scientific community through professional associations and academic teaching. He has served as Member of the Board and President of the French Drug Metabolism and Pharmacokinetics Society (GMP, 2012-2016) and is currently part of its Scientific Committee.
Vassilios also contributes to a M.Sc. program at Paris University and mentors PharmD candidates.